Keros Therapeutics, Inc.(KROS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

KROS Keros Therapeutics, Inc.

交易中 12-26 14:42:49 EST

20.98

-0.38

-1.78%

最高21.45	最低20.95	成交量17.43万
今开21.45	昨收21.36	日振幅2.34%
总市值6.39亿	流通市值4.73亿	总股本3,047万
成交额367.11万	换手率0.77%	流通股本2,255万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"KROS","market":"US","secType":"STK","nameCN":"Keros Therapeutics, Inc.","latestPrice":20.98,"timestamp":1766778157579,"preClose":21.36,"halted":0,"volume":174253,"delay":0,"floatShares":22552100,"shares":30466069,"eps":1.574699,"marketStatus":"交易中","change":-0.38,"latestTime":"12-26 14:42:49 EST","open":21.45,"high":21.45,"low":20.95,"amount":3671065.667838,"amplitude":0.023408,"askPrice":20.99,"askSize":1354,"bidPrice":20.97,"bidSize":868,"shortable":3,"etf":0,"ttmEps":1.574699,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1766782800000},"marketStatusCode":2,"adr":0,"listingDate":1586318400000,"exchange":"NASDAQ","adjPreClose":21.36,"preHourTrading":{"tag":"盘前","latestPrice":21.36,"preClose":21.36,"latestTime":"08:00 EST","volume":17,"amount":353.160006,"timestamp":1766754000740},"postHourTrading":{"tag":"盘后","latestPrice":21.36,"preClose":21.36,"latestTime":"14:24 EST","volume":1619,"amount":34590.81,"timestamp":1766604288697},"volumeRatio":0.268806,"impliedVol":0.7127,"impliedVolPercentile":0.5},"requestUrl":"/m/hq/s/KROS","defaultTab":"news","newsList":[{"id":"2576146850","title":"Keros宣布启动要约回购最多1.944亿美元股票计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2576146850","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576146850?lang=zh_cn&edition=full","pubTime":"2025-10-20 21:55","pubTimestamp":1760968500,"startTime":"0","endTime":"0","summary":"美股周一早盘，临床阶段药物开发商Keros Therapeutics（KROS）上涨2.1%，此前该公司宣布启动要约回购最多1.944亿美元自身股票。此举是其更广泛的3.75亿美元资本回报计划的一部分，反映了Keros在战略增长计划中提升股东价值的承诺。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-10-20/doc-infupzmm9828481.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4139","KROS"],"gpt_icon":0},{"id":"2576908972","title":"Keros Therapeutics, Inc.盘中异动 股价大跌5.11%报13.75美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2576908972","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576908972?lang=zh_cn&edition=full","pubTime":"2025-10-17 02:09","pubTimestamp":1760638154,"startTime":"0","endTime":"0","summary":"北京时间2025年10月17日02时09分，Keros Therapeutics, Inc.股票出现异动，股价急速下挫5.11%。Keros Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.72%。Keros Therapeutics, Inc.公司简介：Keros Therapeutics Inc 是一家临床阶段的生物制药公司，专注于发现、开发和商业化新的治疗方法，用于医疗需求未得到满足的患有血液病、肺病和心血管疾病的患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101702091594cd73de&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101702091594cd73de&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","BK4007","KROS","BK4539"],"gpt_icon":0},{"id":"1107238357","title":"Adar1向Keros Therapeutics, Inc.董事会发出公开信，呼吁董事会在战略规划、资本配置及董事会改组方面积极合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1107238357","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107238357?lang=zh_cn&edition=full","pubTime":"2025-08-21 20:31","pubTimestamp":1755779501,"startTime":"0","endTime":"0","summary":"Adar1向Keros Therapeutics, Inc.董事会发出公开信，呼吁董事会在战略规划、资本配置及董事会改组方面积极合作","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KROS","BK4139"],"gpt_icon":0},{"id":"1153686273","title":"异动解读 | Keros Therapeutics盘中大跌5.48%，Q2财报未达市场预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1153686273","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153686273?lang=zh_cn&edition=full","pubTime":"2025-08-07 22:23","pubTimestamp":1754576630,"startTime":"0","endTime":"0","summary":"周四盘中，临床阶段生物制药公司Keros Therapeutics, Inc.股价大跌5.48%，引发市场关注。这一跌幅似乎与公司刚刚发布的2025年第二季度财务报告有关。根据财报，Keros Therapeutics第二季度净亏损为3070万美元，相比2024年同期的4530万美元有所改善。总的来说，尽管财报显示公司亏损有所收窄，但增加的开支和现金使用计划似乎未能满足市场预期，导致股价下跌。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["KROS"],"gpt_icon":0},{"id":"2518785153","title":"Keros Therapeutics, Inc.盘中异动 下午盘快速跳水5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518785153","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518785153?lang=zh_cn&edition=full","pubTime":"2025-03-11 03:08","pubTimestamp":1741633689,"startTime":"0","endTime":"0","summary":"北京时间2025年03月11日03时08分，Keros Therapeutics, Inc.股票出现异动，股价急速下挫5.10%。Keros Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.16%。Keros Therapeutics, Inc.公司简介：Keros Therapeutics Inc 是一家临床阶段的生物制药公司，专注于发现、开发和商业化新的治疗方法，用于医疗需求未得到满足的患有血液病、肺病和心血管疾病的患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031103081098a2dd5d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031103081098a2dd5d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","KROS"],"gpt_icon":0},{"id":"2517856859","title":"Keros Therapeutics, Inc.盘中异动 下午盘股价大涨5.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517856859","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517856859?lang=zh_cn&edition=full","pubTime":"2025-03-05 04:20","pubTimestamp":1741119629,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日04时20分，Keros Therapeutics, Inc.股票出现波动，股价快速上涨5.32%。Keros Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.13%。Keros Therapeutics, Inc.公司简介：Keros Therapeutics Inc 是一家临床阶段的生物制药公司，专注于发现、开发和商业化新的治疗方法，用于医疗需求未得到满足的患有血液病、肺病和心血管疾病的患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305042029a25f65f8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305042029a25f65f8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KROS","BK4139","LENZ"],"gpt_icon":0},{"id":"2516746548","title":"Keros Therapeutics, Inc.2024财年实现净利润-1.87亿美元，同比减少22.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516746548","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516746548?lang=zh_cn&edition=full","pubTime":"2025-03-03 00:01","pubTimestamp":1740931271,"startTime":"0","endTime":"0","summary":"3月3日，Keros Therapeutics, Inc.公布财报，公告显示公司2024财年净利润为-1.87亿美元，同比减少22.22%；其中营业收入为3.55百万美元，同比增加2250.99%，每股基本收益为-5.00美元。从资产负债表来看，Keros Therapeutics, Inc.总负债44.33百万美元，其中短期债务1.98百万美元，资产负债比为0.14，流动比率为0.22。机构评级：截至2025年3月3日，当前有11家机构对Keros Therapeutics, Inc.目标价做出预测，其中目标均价为33.64美元，其中最低目标价为15.00美元，最高目标价为76.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303000149abe4acd1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303000149abe4acd1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KROS","LENZ"],"gpt_icon":0},{"id":"2514338346","title":"富国银行：维持Keros Therapeutics(KROS.US)评级，由增持调整至增持评级, 目标价由28.00美元调整至26.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514338346","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514338346?lang=zh_cn&edition=full","pubTime":"2025-02-28 01:11","pubTimestamp":1740676297,"startTime":"0","endTime":"0","summary":"富国银行：维持Keros Therapeutics(KROS.US)评级，由增持调整至增持评级, 目标价由28.00美元调整至26.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/28011148441551.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","KROS"],"gpt_icon":0},{"id":"1125438716","title":"Keros Therapeutics 第四季度每股收益为$(1.14)，低于预期$(0.96)，销售额为304万美元，低于预期1542万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1125438716","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125438716?lang=zh_cn&edition=full","pubTime":"2025-02-27 05:33","pubTimestamp":1740605622,"startTime":"0","endTime":"0","summary":"Keros Therapeutics(LENZ)第四季度每股收益$(1.14)，低于预期$(0.96)，销售额304万美元，低于预期1542万美元以上内容来自Benzinga Earnings专栏，原文如下：Keros $Therapeutics(LENZ)$ Q4 EPS $(1.14) Misses $(0.96) Estimate, Sales $3.04M Miss $15.42M Estimate","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KROS","LENZ"],"gpt_icon":0},{"id":"1166835000","title":"“减脂不减肌”：药企竞逐下一代减肥药新突破","url":"https://stock-news.laohu8.com/highlight/detail?id=1166835000","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166835000?lang=zh_cn&edition=full","pubTime":"2025-02-20 17:58","pubTimestamp":1740045485,"startTime":"0","endTime":"0","summary":"罗氏计划今年启动中期试验，将其与自研GLP-1减肥候选药CT-388联用。BiohavenBiohaven在一项早期肥胖试验中评估其靶向肌肉生长抑制素的药物taldefgrobep alfa。该药虽未改善脊髓性肌萎缩症患者的运动功能，但减少了总体脂肪量，并在去脂体重和骨密度方面优于安慰剂。公司将在男性肥胖患者的早期研究中评估安全性，数据预计2025年一季度公布。","market":"us","thumbnail":"https://community-static.tradeup.com/news/f13f2eb23080965f77e2c21530116841","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/f13f2eb23080965f77e2c21530116841"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"“减脂不减肌”：药企竞逐下一代减肥药新突破","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SRRK","KROS","AZN","ARWR","ELAB","REGN","VERU","RHHBY","LLY"],"gpt_icon":1},{"id":"2511918296","title":"Keros Therapeutics, Inc.盘中异动 早盘急速上涨5.32%报10.69美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511918296","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511918296?lang=zh_cn&edition=full","pubTime":"2025-02-14 22:49","pubTimestamp":1739544545,"startTime":"0","endTime":"0","summary":"北京时间2025年02月14日22时49分，Keros Therapeutics, Inc.股票出现异动，股价大幅上涨5.32%。Keros Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.41%。Keros Therapeutics, Inc.公司简介：Keros Therapeutics Inc 是一家临床阶段的生物制药公司，专注于发现、开发和商业化新的治疗方法，用于医疗需求未得到满足的患有血液病、肺病和心血管疾病的患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214224905a2460546&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214224905a2460546&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","KROS"],"gpt_icon":0},{"id":"2509270755","title":"Keros Therapeutics, Inc.盘中异动 大幅上涨5.03%报11.69美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509270755","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509270755?lang=zh_cn&edition=full","pubTime":"2025-02-06 23:20","pubTimestamp":1738855237,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日23时20分，Keros Therapeutics, Inc.股票出现波动，股价快速上涨5.03%。Keros Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.10%。Keros Therapeutics, Inc.公司简介：Keros Therapeutics Inc 是一家临床阶段的生物制药公司，专注于发现、开发和商业化新的治疗方法，用于医疗需求未得到满足的患有血液病、肺病和心血管疾病的患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206232037961a218e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206232037961a218e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KROS","LENZ","BK4139"],"gpt_icon":0},{"id":"2505958026","title":"Keros Therapeutics, Inc.盘中异动 股价大涨5.00%报11.96美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2505958026","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505958026?lang=zh_cn&edition=full","pubTime":"2025-01-24 04:54","pubTimestamp":1737665660,"startTime":"0","endTime":"0","summary":"北京时间2025年01月24日04时54分，Keros Therapeutics, Inc.股票出现异动，股价快速上涨5.00%。Keros Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.77%。消息层面，截至04时54分，《坎托菲茨杰拉德公司：下调Keros Therapeutics评级》资讯为影响Keros Therapeutics, Inc.的重要信息。该信息摘要如下：坎托菲茨杰拉德公司：下调keros Therapeutics评级，由增持调整至中性评级。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250124045420abb6447e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250124045420abb6447e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KROS","BK4139","LENZ"],"gpt_icon":0},{"id":"2505209694","title":"坎托菲茨杰拉德公司：下调Keros Therapeutics评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2505209694","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505209694?lang=zh_cn&edition=full","pubTime":"2025-01-22 00:59","pubTimestamp":1737478781,"startTime":"0","endTime":"0","summary":"坎托菲茨杰拉德公司：下调keros Therapeutics(KROS.US)评级，由增持调整至中性评级。Keros Therapeutics(KROS.US)公司简介：Keros Therapeutics Inc是一家临床阶段的生物制药公司，专注于发现、开发和商业化新的治疗方法，用于医疗需求未得到满足的患有血液病、肺病和心血管疾病的患者。该公司的蛋白治疗候选产品KER-050正在开发中，用于治疗骨髓增生异常综合征(MDS)患者和骨髓纤维化患者的低血细胞计数或细胞减少症，包括贫血和血小板减少症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250122010506abb367b8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250122010506abb367b8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KROS","LENZ"],"gpt_icon":0},{"id":"2505420651","title":"坎托菲茨杰拉德公司：下调Keros Therapeutics(KROS.US)评级，由增持调整至中性评级。","url":"https://stock-news.laohu8.com/highlight/detail?id=2505420651","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505420651?lang=zh_cn&edition=full","pubTime":"2025-01-22 00:41","pubTimestamp":1737477700,"startTime":"0","endTime":"0","summary":"坎托菲茨杰拉德公司：下调Keros Therapeutics(KROS.US)评级，由增持调整至中性评级。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/22004147678749.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["KROS","LENZ"],"gpt_icon":0},{"id":"2505427166","title":"Keros Therapeutics, Inc.盘中异动 股价大涨5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2505427166","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505427166?lang=zh_cn&edition=full","pubTime":"2025-01-21 22:33","pubTimestamp":1737469993,"startTime":"0","endTime":"0","summary":"北京时间2025年01月21日22时33分，Keros Therapeutics, Inc.股票出现异动，股价急速上涨5.06%。Keros Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.89%。Keros Therapeutics, Inc.公司简介：Keros Therapeutics Inc 是一家临床阶段的生物制药公司，专注于发现、开发和商业化新的治疗方法，用于医疗需求未得到满足的患有血液病、肺病和心血管疾病的患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250121223313986e333c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250121223313986e333c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KROS","LENZ","BK4139"],"gpt_icon":0},{"id":"2504190183","title":"Piper Sandler：维持Keros Therapeutics(KROS.US)评级，由增持调整至增持评级, 目标价由40.00美元调整至15.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2504190183","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504190183?lang=zh_cn&edition=full","pubTime":"2025-01-18 02:24","pubTimestamp":1737138299,"startTime":"0","endTime":"0","summary":"Piper Sandler：维持Keros Therapeutics(KROS.US)评级，由增持调整至增持评级, 目标价由40.00美元调整至15.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/18022447578429.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["KROS","LENZ"],"gpt_icon":0},{"id":"2504196967","title":"Wedbush：下调Keros Therapeutics(KROS.US)评级，由优于大市调整至中性评级, 目标价由47.00美元调整至15.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2504196967","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504196967?lang=zh_cn&edition=full","pubTime":"2025-01-18 00:32","pubTimestamp":1737131532,"startTime":"0","endTime":"0","summary":"Wedbush：下调Keros Therapeutics(KROS.US)评级，由优于大市调整至中性评级, 目标价由47.00美元调整至15.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/18003247578206.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","KROS"],"gpt_icon":0},{"id":"2504161951","title":"Keros Therapeutics, Inc.盘中异动 急速上涨5.13%报11.06美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2504161951","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504161951?lang=zh_cn&edition=full","pubTime":"2025-01-17 22:30","pubTimestamp":1737124251,"startTime":"0","endTime":"0","summary":"北京时间2025年01月17日22时30分，Keros Therapeutics, Inc.股票出现波动，股价快速拉升5.13%。Keros Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。Keros Therapeutics, Inc.公司简介：Keros Therapeutics Inc 是一家临床阶段的生物制药公司，专注于发现、开发和商业化新的治疗方法，用于医疗需求未得到满足的患有血液病、肺病和心血管疾病的患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250117223051960796bd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250117223051960796bd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KROS","LENZ","BK4139"],"gpt_icon":0},{"id":"2504444249","title":"Scotiabank：维持Keros Therapeutics(KROS.US)评级，由跑赢大盘调整至跑赢大盘评级, 目标价由44.00美元调整至41.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2504444249","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504444249?lang=zh_cn&edition=full","pubTime":"2025-01-17 03:52","pubTimestamp":1737057175,"startTime":"0","endTime":"0","summary":"Scotiabank：维持Keros Therapeutics(KROS.US)评级，由跑赢大盘调整至跑赢大盘评级, 目标价由44.00美元调整至41.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/17035247536342.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","KROS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kerostx.com","stockEarnings":[{"period":"1week","weight":0.0254},{"period":"1month","weight":0.2557},{"period":"3month","weight":0.3519},{"period":"6month","weight":0.5834},{"period":"1year","weight":0.2783},{"period":"ytd","weight":0.3493}],"compareEarnings":[{"period":"1week","weight":0.0283},{"period":"1month","weight":0.0324},{"period":"3month","weight":0.0491},{"period":"6month","weight":0.1227},{"period":"1year","weight":0.1481},{"period":"ytd","weight":0.178}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Keros Therapeutics, Inc.最初于2015年12月根据特拉华州法律注册成立。该公司是一家临床阶段生物制药公司，专注于为血液学和肌肉骨骼疾病患者开发和商业化新型治疗方法。该公司在了解转化生长因子β（一种蛋白质家族）的作用方面处于领先地位，它是红细胞和血小板生产以及肌肉和骨骼生长、修复和维护的主要调节者。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.013304},{"month":2,"riseRate":0.6,"avgChangeRate":0.081109},{"month":3,"riseRate":0.2,"avgChangeRate":-0.068893},{"month":4,"riseRate":0.4,"avgChangeRate":0.047555},{"month":5,"riseRate":0.166667,"avgChangeRate":-0.095298},{"month":6,"riseRate":0.166667,"avgChangeRate":-0.056826},{"month":7,"riseRate":0.666667,"avgChangeRate":0.015981},{"month":8,"riseRate":0.5,"avgChangeRate":0.081534},{"month":9,"riseRate":0.666667,"avgChangeRate":0.03143},{"month":10,"riseRate":0.5,"avgChangeRate":0.115174},{"month":11,"riseRate":0.666667,"avgChangeRate":0.148933},{"month":12,"riseRate":0.5,"avgChangeRate":-0.041368}],"exchange":"NASDAQ","name":"Keros Therapeutics, Inc.","nameEN":"Keros Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Keros Therapeutics, Inc.(KROS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Keros Therapeutics, Inc.(KROS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Keros Therapeutics, Inc.,KROS,Keros Therapeutics, Inc.股票,Keros Therapeutics, Inc.股票老虎,Keros Therapeutics, Inc.股票老虎国际,Keros Therapeutics, Inc.行情,Keros Therapeutics, Inc.股票行情,Keros Therapeutics, Inc.股价,Keros Therapeutics, Inc.股市,Keros Therapeutics, Inc.股票价格,Keros Therapeutics, Inc.股票交易,Keros Therapeutics, Inc.股票购买,Keros Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Keros Therapeutics, Inc.(KROS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Keros Therapeutics, Inc.(KROS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}